The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.
A. A. Adjei
No relevant relationships to disclose
J. A. Sosman
Consultant or Advisory Role - Roche (U)
Honoraria - Millennium; Roche
R. E. Martell
No relevant relationships to disclose
G. K. Dy
No relevant relationships to disclose
L. W. Goff
No relevant relationships to disclose
W. W. Ma
No relevant relationships to disclose
L. Horn
No relevant relationships to disclose
G. J. Fetterly
No relevant relationships to disclose
S. A. Michael
No relevant relationships to disclose
J. A. Means
No relevant relationships to disclose
F. Chai
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
M. Lamar
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
G. M. Strauss
No relevant relationships to disclose
W. Chiang
No relevant relationships to disclose
J. Jarboe
No relevant relationships to disclose
B. E. Schwartz
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
I. Puzanov
Stock Ownership - ArQule (I)